PT  - JOURNAL ARTICLE
AU  - Whitlock, Nichelle C.
AU  - White, Margaret E.
AU  - Capaldo, Brian J.
AU  - Ku, Anson T.
AU  - Agarwal, Supreet
AU  - Fang, Lei
AU  - Wilkinson, Scott
AU  - Trostel, Shana Y.
AU  - Shi, Zhen-Dan
AU  - Basuli, Falguni
AU  - Wong, Karen
AU  - Jagoda, Elaine M.
AU  - Kelly, Kathleen
AU  - Choyke, Peter L.
AU  - Sowalsky, Adam G.
TI  - Progression of prostate cancer reprograms MYC-mediated lipid metabolism via lysine methyltransferase 2A
AID  - 10.1101/2022.06.04.22276001
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.06.04.22276001
4099  - http://medrxiv.org/content/early/2022/06/06/2022.06.04.22276001.short
4100  - http://medrxiv.org/content/early/2022/06/06/2022.06.04.22276001.full
AB  - Background The activities of MYC, the androgen receptor, and its associated pioneer factors demonstrate substantial reprogramming between early and advanced prostate cancer. Although previous studies have shown a shift in cellular metabolic requirements associated with prostate cancer progression, the epigenetic regulation of these processes is incompletely described. Here, we have integrated chromatin immunoprecipitation sequencing (ChIP-seq) and whole-transcriptome sequencing to identify novel regulators of metabolism in advanced prostate tumors characterized by elevated MYC activity.Results Using ChIP-seq against MYC, HOXB13, and AR in LNCaP cells, we observed redistribution of co-bound sites suggestive of differential KMT2A activity as a function of MYC expression. In a cohort of 177 laser-capture microdissected foci of prostate tumors, KMT2A expression was positively correlated with MYC activity, AR activity, and HOXB13 expression, but decreased with tumor grade severity. However, KMT2A expression was negatively correlated with these factors in 25 LuCaP patient-derived xenograft models of advanced prostate cancer and 99 laser-capture microdissected foci of metastatic castration-resistant prostate cancer. Stratified by KMT2A expression, ChIP-seq against AR and HOXB13 in 15 LuCaP patient-derived xenografts showed an inverse association with sites involving genes implicated in lipid metabolism, including the arachidonic acid metabolic enzyme PLA2G4F. LuCaP patient-derived xenograft models grown as organoids recapitulated the inverse association between KMT2A expression and fluorine-18 labeled arachidonic acid uptake in vitro.Conclusions Our study demonstrates that the epigenetic activity of transcription factor oncogenes exhibits a shift during prostate cancer progression with distinctive phenotypic effects on metabolism. These epigenetically driven changes in lipid metabolism may serve as novel targets for the development of novel imaging agents and therapeutics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Prostate Cancer Foundation (Young Investigator Awards to A.T.K and S.W.) the Department of Defense Prostate Cancer Research Program (W81XWH-19-1-0712 to S.W., W81XWH-16-1-0433 to A.G.S.), and the Intramural Research Program of the NIH, National Cancer Institute. These funding bodies had no role in the design of the study and collection, analysis, and interpretation of data, nor in writing the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Boards of the National Institutes of Health, Beth Israel Deaconess Medical Center, and Dana-Farber/Harvard Cancer Center gave approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data underlying this article have been deposited in Database of Genotypes and Phenotypes (dbGaP) and Gene Expression Omnibus (GEO) at https://www.ncbi.nlm.nih.gov/gap/ and https://www.ncbi.nlm.nih.gov/geo/, respectively, and can be accessed with phs001813.v2.p1 (dbGaP), phs001938.v3.p1 (dbGaP) and GSE135942 (GEO). https://www.ncbi.nlm.nih.gov/geo/ https://www.ncbi.nlm.nih.gov/gap/ [18F]ArAFluorine-18 labeled arachidonic acidARAndrogen receptorArAArachidonic acidCRPCCastration-resistant prostate cancermCRPCMetastatic castration-resistant prostate cancerPCaProstate cancerPDXPatient-derived xenograftTFTranscription factor